MS Society funds research to explore role of gut in pediatric MS
MS Society funds new research to explore the role of the gut in pediatric multiple sclerosis
November 23, 2015 – Vancouver, BC – As few as five per cent of new cases of Multiple Sclerosis (MS) are diagnosed in children, but to better understand the disease, children may be our brightest source of hope. The Multiple Sclerosis Society of Canada and Multiple Sclerosis Scientific Research Foundation have announced new funding that will propel research into pediatric MS and the gut microbiome’s role in autoimmune and brain diseases.
“This small percentage of MS cases actually represents a critical opportunity to potentially discover what causes MS,” says Dr. Helen Tremlett, Canada Research Chair and PI on the gut microbiome project that recently received the funding and will link in with the broader Canadian Demyelinating Disease (CDD) study led by Dr. Brenda Banwell. “Through the families, we’re typically able to get a more complete health and lifestyle history, and we’re closer to the onset of the disease; there is less history to sort through with kids, and we’re better able to pinpoint when the disease took hold.”
The MS Society of Canada and MS Scientific Research
Foundation have provided $500,000 over three years for this
research as the fifth stage in the ongoing CDD study.
The CDD study – headed by pediatric MS neurologist Dr. Brenda
Banwell from The Hospital for Sick Children and Children’s
Hospital of Philadelphia (CHOP) – includes all 17 pediatric
health care institutions in Canada, six additional Canadian sites
as well CHOP.
“The launch of this study represents an important advancement in pediatric research and serves as a great example of building on research progress,” says Dr. Karen Lee, Vice President, Research, MS Society of Canada. “I look forward to seeing what Dr. Helen Tremlett and her team will uncover in terms of the role that the natural bacteria that lives within us plays in MS. It is exciting that they will be collecting information from one of the most comprehensive pediatric MS cohorts in the world, established right here in Canada under the leadership of Dr. Banwell and with support from the MS Society and MS Scientific Research Foundation.”
With such excitement and possibility, enrolment in this first-of-its-kind multi-centre study has already begun. Dr. Tremlett, for her part, has been at the forefront of research linking MS and the gut microbiome – her work with Dr. Emmanuelle Waubant at the University of California, San Francisco, offers preliminary data in support of a link between the gut and neurodegenerative disease, specifically pediatric MS. This study will also bring together, for the first time, both the Canadian and US Pediatric MS and demyelinating disease networks.
“The microbiome is so important for a number of reasons,” says
Dr. Tremlett. “The bacteria in your gut educates your immune
system, and vice versa. We already know there’s a gut-brain
connection, directly through the vagus nerve for instance, also
via the immune system and perhaps through serotonin production –
around 90 per cent of which is produced in your gut. Preliminary
data shows we’re on the right track with this – we’re examining
the link and trying to understand the influence of the gut
microbiota in MS and MS on the gut microbiota.” Dr. Tremlett’s
research at the University of California, where she recently
spent sabbatical time, has focused on a cohort of 18 children
with MS and 17 healthy children.
“We discovered that while there was no huge difference in the
overall composition, richness and diversity of the gut microbiota
between the two groups of children, some very interesting subtle
differences were observed and the MS drug treatments appeared
influential,” says Dr. Tremlett. “We really believe we’re onto
something important in pursuing these lines of research.”
- 30 -
About multiple sclerosis, the MS Society of Canada and
the Multiple Sclerosis Scientific Research
Canada has the highest rate of multiple sclerosis in the world. MS is a chronic, often disabling disease of the central nervous system comprising the brain, spinal cord and optic nerve. It is one of the most common neurological diseases affecting young adults in Canada. Most people with MS are diagnosed between the ages of 15 and 40, and the unpredictable effects of MS last for the rest of their lives. The MS Society provides services to people with MS and their families and funds research to find the cause and cure for this disease. The Multiple Sclerosis Scientific Research Foundation funds large, innovative, multi-centre collaborative studies that will lead to major advances in the field of MS. A unique Canadian resource, the Foundation’s main funding source is the MS Society of Canada. Please visit mssociety.ca or call 1-800-268-7582 to make a donation or for more information.
About Djavad Mowafaghian Centre for Brain Health
The Djavad Mowafaghian Centre for Brain Health comprises more than 250 investigators with multidisciplinary expertise, bridging basic science and clinical care in a state-of-the-art facility on UBC’s Point Grey campus. The Centre provides opportunities for education, collaboration, and interaction with patients from across BC. The Centre is the largest and most comprehensive brain care and research centre in Canada, and is a partnership of the UBC Faculty of Medicine, Vancouver Coastal Health, and Vancouver Coastal Health Research Institute. Website: www.centreforbrainhealth.ca; Twitter: twitter.com/DMCBrainHealth.
Lindsay Gulin, MS Society of Canada
1-800-268-7582 ext. 3245, email@example.com
Emily Wight, Djavad Mowafaghian Centre for Brain Health